Tag: tech transfer

Addressing Late-Identified Excipient Incompatibility During Tech Transfer In the realm of pharmaceutical manufacturing, excipient incompatibility can emerge as a significant issue during the tech transfer phase of product development. Identifying…

Managing Late-Stage Excipient Incompatibility During Scale-Up Preparation Accurate identification and management of excipient incompatibilities during the late stages of formulation development can be a significant challenge in pharmaceutical manufacturing. Discovering…

Managing Bioavailability Risks Identified During Early Drug Development In the dynamic environment of pharmaceutical development, identifying bioavailability risks early in the formulation process is crucial to prevent costly late-stage reformulations.…

Addressing Scalability Issues During Regulatory Review of Pharmaceutical Prototypes In the pharmaceutical manufacturing sector, the transition from prototype formulation to scalable production is critical. However, many firms encounter problems where…

How to Address Formulation Stability Failures During Regulatory Reviews Formulation stability failures during regulatory reviews can have significant implications for drug approval, leading to delays, additional costs, and potential market…

Redesigning Formulation Strategy When Stability Targets Fail During Tech Transfer Stability failures during tech transfer can present significant challenges for pharmaceutical manufacturers. As you navigate this complex landscape, understanding the…

Addressing Scalability Issues of Prototypes During IND/NDA Filings: A Practical Playbook In the pharmaceutical landscape, the transition from prototype formulations to scalable production systems is a significant hurdle that can…

Addressing Unexplained Dissolution Variability During Scale-Up Preparation Dissolution variability is a persistent challenge in pharmaceutical manufacturing, particularly during scale-up preparation. It can lead to unpredictable drug release profiles and complicate…

Enhancing the Scalability of Prototypes During Early Development Stages During the early stages of pharmaceutical development, companies often encounter challenges when their prototypes are not scalable. This scenario can lead…

Addressing Missing QbD Elements in IND/NDA Filings to Avoid Late-Stage Reformulation The pharmaceutical development landscape has increasingly emphasized Quality by Design (QbD) to ensure more predictable outcomes from IND/NDA filings.…

Addressing Missing QbD Elements in IND/NDA Filings to Prevent Late-Stage Reformulations In today’s rapidly evolving pharmaceutical landscape, ensuring a robust Quality by Design (QbD) framework during the Investigational New Drug…

Managing Bioavailability Risks During Early Development: A Comprehensive Playbook Bioavailability risk flagged during early development can significantly impact project timelines and regulatory approval pathways. Understanding the early indicators and having…